Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 175, Issue 3, Pages 462-466Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.14324
Keywords
chronic lymphocytic leukaemia; ibrutinib; atrial fibrillation
Categories
Funding
- Janssen
Ask authors/readers for more resources
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 38months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available